A VISIONaerie® approach
We discover, develop, and commercialize first-in-class therapies for the treatment of patients with glaucoma, retinal diseases and other diseases of the eye
Press Release
Aerie Pharmaceuticals Receives Positive CHMP Opinion for Rhokiinsa®... Aerie Pharmaceuticals Submits Prior Approval Supplement to the U.S.... Aerie Pharmaceuticals Announces Full Exercise by Initial Purchasers of...STOCK Quote
NASDAQ: AERI
$19.71USD
Oct 14, 4:00 PM ET
VOLUME
0
DAY LOW/HIGH
$19.12/$20.38
52 - WEEK LOW/HIGH
$17.51/$60.81
